Helus Pharma Inc Ordinary Shares HELP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
-
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
-
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
-
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
-
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Trading Information
- Previous Close Price
- $10.09
- Day Range
- $10.71–11.57
- 52-Week Range
- $3.76–11.62
- Bid/Ask
- $10.23 / $11.64
- Shares Outstanding
- 61.98M
- Market Cap
- $712.20M
- Volume/Avg
- 844 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 50
- Website
- https://www.helus.com
Valuation
|
Metric
|
HELP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.07 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HELP
|
|---|---|
Quick Ratio | 8.38 |
Current Ratio | 9.52 |
Interest Coverage | — |
Quick Ratio
HELP
Profitability
|
Metric
|
HELP
|
|---|---|
Return on Assets (Normalized) | −59.35% |
Return on Equity (Normalized) | −107.03% |
Return on Invested Capital (Normalized) | −66.31% |
Return on Assets
HELP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|kK#chKT | LOCK|QRC%g | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!<V@Yr@ | LOCK|BLr>k | $82B | |||
| argenx SE ADR
ARGX
| LOCK|^N@gRKz | LOCK|Q# | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|hn$wt!hF | LOCK|ChFw | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&lz@^@h | LOCK|d#g | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|X&hL>jc | LOCK|&kxr | $30B | |||
| Moderna Inc
MRNA
| LOCK|v<jl?& | LOCK|?^ | $25B | |||
| Incyte Corp
INCY
| LOCK|C!@<!dt | LOCK|^# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|K#<>$nN | LOCK|$@ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|KvP@B<C | LOCK|zY | $16B |
United States